Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 85Other hematologic neoplasm 12Dermatologic 11Myeloid 2Genitourinary 2Thoracic 1Sarcoma 1Other solid neoplasm 1

Conditions

Mesothelioma, Malignant 1

Interventions

Cisplatin 60Carboplatin 55Cyclophosphamide 47Pemetrexed 45Irinotecan 33pembrolizumab 32Paclitaxel 29Etoposide 29Gemcitabine 28Nivolumab 24Bevacizumab 24Interviews as Topic 23Vincristine 22Capecitabine 22Topotecan 20Filgrastim 20Early Intervention, Educational 20fludarabine 19Oxaliplatin 19Docetaxel 19Specimen Handling 18Drug Therapy 18Temozolomide 17Sorafenib 17Leucovorin 17Everolimus 17Educational Status 17Radiotherapy 16Methods 16Fluorouracil 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Brentuximab Vedotin × Other solid neoplasm × Clear all
NCT03007030 2026-05-15

Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery

M.D. Anderson Cancer Center

Phase 2 Recruiting
55 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡